David A. Santos - 29 Jan 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Commercial Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
29 Jan 2025
Net transactions value
$0
Form type
4
Filing time
31 Jan 2025, 18:47:07 UTC
Previous filing
26 Nov 2024
Next filing
06 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +19,717 +55% $0.000000 55,625 29 Jan 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (Right to Buy) Award $0 +14,788 $0.000000 14,788 29 Jan 2025 Common Stock 14,788 $22.49 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026.
F2 This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F3 Includes 999 shares acquired under the Issuer's stock purchase plan.
F4 The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period.